Symptom domains of schizophrenia: the role of atypical antipsychotic agents (Q36626242)

15 August 2017

1 reference

title

Symptom domains of schizophrenia: the role of atypical antipsychotic agents (English)

1 reference

15 August 2017

0 references

Simon Burton

1

1 reference

PubMed ID

17046984

15 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

Journal of Psychopharmacology

15 August 2017

1 reference

15 August 2017

20

1 reference

15 August 2017

6 Suppl

1 reference

15 August 2017

6-19

1 reference

Insight in persons with schizophrenia: effects of switching from conventional neuroleptics to atypical antipsychotics

15 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Remission in schizophrenia: proposed criteria and rationale for consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Predicting quality of life from symptomatology in schizophrenia at exacerbation and stabilization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Quality of life in schizophrenia: insight and subjective response to neuroleptics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

A meta-analysis of the efficacy of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Detection and management of comorbidity in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

What are the functional consequences of neurocognitive deficits in schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Cognitive impairment and negative symptoms in geriatric chronic schizophrenic patients: a follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Subjective well-being and quality of life under atypical antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Drug treatment of the negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Effects of quetiapine on cognitive functions in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Chronic mental patients: the quality of life issue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Risperidone in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

The longitudinal relationship of clinical symptoms, cognitive functioning, and adaptive life in geriatric schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Investigation of a possible diencephalic pathology in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Age, gender and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Judgments of quality of life of individuals with severe mental disorders: Patient self-report versus provider perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Insight into illness and attitudes toward medications among inpatients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Diagnosis of secondary depression in schizophrenia: implications for DSM-IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

The effect of risperidone on cognition in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Quetiapine has a direct effect on the negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

The many faces of Akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

'Akinetic Depression' in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Does cognitive function improve with quetiapine in comparison to haloperidol?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786806071237

21 January 2018

Identifiers

DOI

10.1177/1359786806071237

1 reference

15 August 2017

1 reference

PubMed ID

17046984